

In the claims:

1-6. (canceled).

7. (currently amended): A method for the treatment of ovarian cancer comprising administering a therapeutically effective amount of an antibody which specifically interacts with a CDCP1 polypeptide comprising ~~or consisting of the amino acid sequence of SEQ ID NO:1~~ or residues 30-667 of SEQ ID NO: 1.

8. (canceled).

9. (previously presented): The method according to claim 7, wherein the antibody is monoclonal, polyclonal, chimeric, humanised or bispecific, or is conjugated to a therapeutic moiety, detectable label, second antibody or a fragment thereof, an effector or reporter molecule, a cytotoxic agent or cytokine.

10-27. (canceled).

28. (previously presented): The method according to claim 9, wherein the antibody is a Fab, Fab', or Fab'₂ fragment.

29. (previously presented): The method according to claim 9, wherein the therapeutic moiety is a toxin or a radionuclide.